Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527453 | 0.86 | MAPT (0.76) | L3MBTL1MAPTGAAKMT2AMEN1 | |
| SCHEMBL1592638 | 0.84 | ALDH1A1 (0.63) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2544298 | 0.83 | ALDH1A1 (0.62) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL6951550 | 0.82 | GAA (0.69) | L3MBTL1MAPTGAAKMT2AMEN1 | |
| SCHEMBL4075002 | 0.81 | L3MBTL1 (1.00) | L3MBTL1MAPTGAAKMT2AMEN1 | |
| SCHEMBL12490995 | 0.81 | L3MBTL1 (0.74) | L3MBTL1MAPTGAAKMT2AMEN1 | |
| SCHEMBL1592720 | 0.80 | CNR2 (0.72) | L3MBTL1MAPTALDH1A1 | |
| SCHEMBL12793245 | 0.79 | POLB (0.88) | L3MBTL1GAAKMT2AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2542957 | 0.79 | CNR2 (0.71) | L3MBTL1MAPTALDH1A1 | |
| SCHEMBL12010889 | 0.79 | ALDH1A1 (0.78) | L3MBTL1MAPTGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092490-A1 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2011-04-21 | — | — | US | disclosed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| WO-2009118567-A2 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2009-10-01 | — | — | WO | disclosed |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1799652-A1 | N-BENZENESULFONYL SUBSTITUTED ANILINO-PYRIMIDINE ANALOGS | Wyeth (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044457-A1 | N-BENZENESULFONYL SUBSTITUTED ANILINO-PYRIMIDINE ANALOGS | WYETH (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | HPRT1, APRT, NUDT1 | L3MBTL1 1904/4885MAPT 1048/4885GAA 4527/4885 |
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | L3MBTL1 2308/4885MAPT 2684/4885GAA 4024/4885 |
| US-20110092490-A1 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | HRH2, HRH3, HRH4 | L3MBTL1 4579/4885MAPT 4355/4885GAA 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.